Drugs / V565
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03705117 | May → Oct 2017 | ulcerative colitis | VHsquared Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03010787 | Sep 2015 → Mar 2016 | Crohn disease | VHsquared Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02976129 | Dec 2016 → Mar 2019 | Crohn disease | VHsquared Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-08 | Relay Therapeutics, Inc. | Results Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor relaytx.com ↗
Radiographic tumor shrinkage and complete clearance of circulating tumor DNA (ctDNA) in 70% of patients with acquired resistance mutations (N=10), including molecular brake (N550) and gatekeeper (V565) mutations, suggesting the potential for RLY-4008 to treat or prevent on-target acquired resistance. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-08 | Relay Therapeutics, Inc. | Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor relaytx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V565 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03705117 ↗ |
| Modality | Protein / enzyme biologic | “oral Domain Antibody V565” NCT03705117 ↗ |
| Route | Oral | “orally” NCT02976129 ↗ |
| Target | TNF | “binds to TNF and reduces inflammation” NCT03705117 ↗ |